TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Ascentage Pharma Group International Inc.
Ascentage Pharma Announces Publication of Olverembatinib Phase Ib Safety, Efficacy and Novel Mechanism Data in Gastrointestinal Stromal Tumors in Nature’s Signal Transduction and Targeted Therapy

Ascentage Pharma published promising Phase Ib clinical trial results for olverembatinib in treating succinate dehydrogenase (SDH) deficient gastrointestinal stromal tumors (GIST), demonstrating a novel mechanism of action by modulating lipid metabolism with a 23.1% objective response rate.

Insights
GOOGL   positive

Listed among key players developing AI and computer vision technologies for healthcare


AAPG   positive

Published promising clinical trial results revealing a novel drug mechanism, demonstrated efficacy in rare tumor treatment, and showed potential breakthrough in addressing unmet medical needs